Association of Sodium-Glucose Cotransporter 2 Inhibitor Treatment With Risk of Hospitalization for Fournier Gangrene Among Men

Dave, Chintan V; Schneeweiss, Sebastian; Patorno, Elisabetta

doi:10.1001/jamainternmed.2019.2813

Record: found
Abstract: not found
Article: not found

Association of Sodium-Glucose Cotransporter 2 Inhibitor Treatment With Risk of Hospitalization for Fournier Gangrene Among Men

Author(s): Chintan V. Dave ¹ , Sebastian Schneeweiss ¹ , Elisabetta Patorno ¹

Publication date Created: November 01 2019

Publication date (Print): November 01 2019

Journal: JAMA Internal Medicine

Publisher: American Medical Association (AMA)

Read this article at

ScienceOpenPublisher PMC

Bookmark

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

This cohort study assesses the association between initiation of sodium-glucose cotransporter 2 (SGLT-2) inhibitor treatment and the risk of hospitalization for Fournier gangrene among men.

Related collections

Most cited references 2

Record: found
Abstract: found
Article: not found

Fournier Gangrene Associated With Sodium–Glucose Cotransporter-2 Inhibitors

Susan Bersoff-Matcha, Christine E Chamberlain, Christian Cao … (2019)

Use of sodium-glucose cotransporter-2 (SGLT2) inhibitors has been associated with Fournier gangrene (FG), a rare urologic emergency characterized by necrotizing infection of the external genitalia, perineum, and perianal region.